Effect of the highly selective and nonpeptide δ opioid receptor agonist TAN-67 on the morphine-induced place preference in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 1, 1996, Pages 177-185

  Suzuki, Tsutomu ^a   Tsuji, Minoru ^a   Mori, Tomohisa ^a   Misawa, Miwa ^a   Endoh, Takashi ^b   Nagase, Hiroshi ^b  

^a HOSHI UNIVERSITY   (Japan)

^b TORAY INDUSTRIES INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,4A,5,12,12AALPHA OCTAHYDRO 4AALPHA (3 HYDROXYPHENYL) 2 METHYLQUINOLINO[2,3 G]ISOQUINOLINE; 7 BENZYLIDENENALTREXONE; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DOPAMINE; MORPHINE; NALTRIBEN; NALTRINDOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOSE RESPONSE; DRUG POTENTIATION; LIMBIC CORTEX; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALGESICS; ANIMALS; BENZYLIDENE COMPOUNDS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALINS; LIMBIC SYSTEM; MALE; MICE; MORPHINE; NALTREXONE; QUINOLINES; RECEPTORS, OPIOID, DELTA; REWARD;

EID: 0030434065     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. ABDELHAMIDE, E. E., SULTANA, M., PORTOGHESE, P. S. AND TAKEMORI, A. E.: Selective blockade of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmacol. Exp. Ther. 258: 299-303, 1991.
2. BALS-KUBIC, R., SHIPPENBERG, T. S. AND HERZ, A.: Involvement of central μ and δ receptors in mediating the reinforcing effects of β-endorphin in rat. Eur. J. Pharmacol. 175: 63-69, 1990.
3. BALS-KUBIC, R., ABUBLEITNEK, A., HERZ, A. AND SHIPPENBEBG, T. S.: Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J. Pharmacol. Exp. Ther. 264: 489-495, 1993.
4. BLOOM, F. E.: The endorphins: A growing family of pharmacologically pertinent peptides. Ann. Rev. Pharmacol. Toxicol. 23: 151-170, 1983.
5. BOZARTH, M. A.: Neuroanatomical boundaries of the reward-relevant opiate-receptor field in the ventral tegmental area as mapped by the conditioned place preference method in rats. Brain Res. 414: 77-84, 1987.
6. BRITT, M. D. AND WISE, R. A.: Ventral tegmental site of opiate reward: Antagonism by a hydrophilic opiate receptor blocker. Brain Res. 258: 105-108, 1982.
7. CHANG, K. J., SU, Y. F., BRENT, D. A. AND CHANG, J. K.: Isolation of a specific μ-opioid receptor peptide, morphicetin, from an enzymatic digest of milk proteins. J. Biol. Chem. 260: 9706-9712, 1985.
8. DEVINE, D. P., LEONE, P., POCOCK, D. AND WISE, R. A.: Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: In vivo microdialysis studies. J. Pharmacol. Exp. Ther. 266: 1236-1246, 1994.
9. 5]-enkephalin (DP-DPE) into the ventral tegmentum of rat. Soc. Neurosci. Abstr. 16: 930, 1990.
10. DEVINE, D. P. AND WISE, R. A.: Self-administration of morphine, DAMGO, and DPDPE into the ventral tegmental area of rats. J. Neurosci. 14: 1978-1984, 1994.
11. DI CHIARA, G. AND IMPERATO, A.: Opposite of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244: 1067-1080, 1988.
12. FUNADA, M., SUZUKI, T., NARITA, M., MISAWA, M. AND NAGASE, H.: Blockade of reward through the activation of κ-opioid receptor in mice. Neuropharmacology 32: 1315-1323, 1993.
13. GACEL, G. M., FOURNIE-ZALUSKI, M. C. AND ROQUES, B. P.: Tyr-D-Ser-Gly-Phe-Leu-Thr, a highly preferential ligand for delta-opioid receptors. FEBS Lett. 118: 245-247, 1980.
14. GILBERT, P. E. AND MARTIN, W. R.; The effects of morphine- and nalorphine-like drugs in the non-dependent, morphine-dependent and cyclazocine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 198: 66-82, 1976.
15. GOEDERS, N. E., LANE, J. D. AND SMITH, J. E.: Self-administration of methionin enkephalin into the nucleus accumbens. Pharmacol. Biochem. Behav. 20: 451-455, 1984.
16. 3H]-β-endorphin binding in brain. Brain Res. 288: 334-337, 1983.
17. HAHN, E. F., CARROLL-BUATTI, M. AND PASTERNAK, G. W.: Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines. J. Neurosci. 2: 572-576, 1981.
18. HUGHES, J., SMITH, T. W., KOSTERLITZ, H. W., FOTHERGILL, L. A., MORGAN, B. A. AND MORRIS, H. R.: Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature (Lond.) 258: 277-279, 1975.
19. JENCK, F., GRATTON, A. AND WISE, R. A.: Opioid receptor subtypes associated with ventral tegmental facilitation of lateral hypothalamic brain stimulation reward. Brain Res. 423: 34-38, 1987.
20. 6]enkephalin and naltrindole 5′-isothiocyanate: Evidence for delta receptor subtypes. J. Pharmacol. Exp. Ther. 257: 1069-1075, 1991.
21. JIANG, Q., MOSBERG, H. I. AND PORRECA, F.: Modulation of the potency and efficacy of mu-mediated antinociception by delta agonists in the mouse. J. Pharmacol. Exp. Ther. 254: 683-689, 1990.
22. 3H]naloxonazine to rat brain membranes. Mol. Pharmacol. 26: 477-483, 1984.
23. KALIVAS, P. W., WIDERLOV, E., STANLEY, D., BREESE, G. AND PRANGE, JR., A. J.: Enkephalin action on the mesolimbic system: A dopamine-dependent and a dopamine-independent increase in locomotor activity. J. Pharmacol. Exp. Ther. 227: 229-237, 1983.
24. LATIMER, L. G., DUFFY, P. AND KALIVAS, P. W.: Mu opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area. J. Pharmacol. Exp. Ther. 241: 328-337, 198.
25. LAWLEY, S. I. AND KANTAK, K. M.: Postconditioning effects of magnesium on cocaine conditioned place preference in mice. Pharmacol. Biochem. Behav. 36:539-546, 1990a.
26. LAWLEY, S. I. AND KANTAK, K. M.: Magnesium-induced conditioned place preference in mice. Pharmacol. Biochem. Behav. 36: 539-545, 1990b.
27. LIU-CHEN, L.-Y., LI, S., WHEELER-ACETO, H. AND COWAN, A.: Effect of intracerebroventricular β-funaltrexamine on μ and δ opioid receptors in the rat: Dichotomy between binding and antinociception. Eur. J. Pharmacol. 203: 195-202, 1991.
28. 1-dependent stereotypies and stimulation of dopamine release in the nucleus accumbens. J. Neurosci. 11: 1565-1576, 1991.
29. LORD, J. A., WATERFIELD, A. A., HUGHES, J. AND KOSTERLITZ, H. W.: Endogenous opioid peptides: Multiple agonists and receptors. Nature (Lond.) 267: 495-499, 1977.
30. MANSOUR, A., KHACHATURIAN, H., LEWIS, M. E., AKIL, H. AND WATSON, S. J.: Anatomy of CNS opioid receptors. Trends Neurosci. 11: 308-314, 1988.
31. MANZANARES, J., DURHAM, R. A., LOOKINGLAND, K. J. AND MOORE, K. E.: δ-Opioid receptor mediated regulation of central dopaminergic neurons in the rat. Eur. J. Pharmacol. 249: 107-112, 1993.
32. MARTIN, W. R., EADES, C. G., THOMPSON, J. A., HUPPLER, R. E. AND GILBERT, P. E.: The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197: 517-532, 1976.
33. MATTHEWS, W. R. AND GERMAN, D. C.: Electrophysiological evidence for excitation of rat ventral tegmental area dopamint neuron by morphine. Neuroscience 11: 617-625, 1984.
34. 2]deltorphin II in mice: Evidence for delta receptor subtypes. J. Pharmacol. Exp. Ther. 258: 583-587, 1991.
35. 2 opioid receptors in the development of morphine dependence in mice. J. Pharmacol. Exp. Ther. 264: 1141-1145, 1993.
36. MOSBERG, H. I., HURST, R., HRUBY, V. J., GEE, K. YAMAMURA, H. I., GALLIGAN, J. J. AND BURKS, T. F.: Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors. Proc. Natl. Acad. Sci. USA 80: 5871-5874, 1983.
37. MUCHA, R. F., VAN DER KOOBY, D., O'SHAUGHNESSY, M. AND BUCENIEKS, P.: Drug reinforcement studied by use of place conditioning in rat. Brain Res. 243: 91-105, 1982.
38. MUCHA, R. F. AND HERZ, A.: Motivational properties of kappa- and mu-opioid receptor agonists studied with place and taste preference conditioning procedure. Psychopharmacology 86: 274-280, 1935.
39. NAGASE, H., WAKITA, H., KAWAI, K., ENDOH, T., MATSUURA, H., TANAKA, C. AND TAKAZAWA, Y.: Syntheses of non-peptidic de ta opioid agonists and their structure activity relationships. Jpn. J. Pharmacol. Suppl. 64: 35, 1994.
40. NARITA, M., SUZUKI, T., FUNADA, M., MISAWA, M. AND NAGASE, H.: Involvement of δ-opioid receptors in the effects of morphine on locomotor activity and the mesolimbic dopaminergic system in mice. Psychopharmacology 111: 423-426, 1993.
41. NEGUS, S. S., BUTELMAN, E. R., CHANG, K.-J., DECOSTA, B., WINGER, G. AND WOODS, J. H.: Behavioral effects of systemically active delta opioid agonist BW373U86 in rhesus monkeys. J. Pharmacol. Exp. Ther. 270: 1025-1034, 1994.
42. OLDS, M. E.: Reinforcing effects of morphine in the nucleus accumbens. Brain Res. 237: 429-440, 1982.
43. PASTERNAK, G. W. AND HAHN, E. F.: Long-acting opiate agonists and antagonists: 14-hydroxydihydromorphinone hydrazones. J. Med. Chem. 23: 674-677, 1980.
44. PERT, A. AND SIVIT, C.: Neuroanatomical focus for morphine and enkephalin-induced hypermotility. Nature (Lond.) 265: 645-647, 1977.
45. PHILLIPS, A. G., LEPIANE, F. G. AND FIBIGER, H. C.: Dopaminergic mediation of reward produced by direct injection of enkephalin into the ventral tegmental area of rat. Life Sci. 33: 2505-2511, 1983.
46. PORTOGHESE, P. S., SULTANA, M. AND TAKEMORI, A. E.: Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist. Eur. J. Pharmacol. 146: 185-186, 1988.
47. PORTOGHESE, P. S., SULTANA, M. AND TAKEMORI, A. E.: Design of petidomimetic δ opioid antagonists using the message-address concept. J. Med. Chem. 33: 1714-1720, 1990.
48. PORTOGHESE, P. S., NAGASE, H., MALONEYHUSS, K. E., LIN, C.-E. AND TAKEMORI, A. E.: Role of spacer and address components in peptidomimetic δ opioid receptor antagonists related to naltrindole. J. Med. Chem. 34: 1715-1720, 1991.
49. 1-opioid receptor antagonist: 7-benzylidenenaltrexone. Eur. J. Pharmacol. 218: 195-196, 1992.
50. ROTHMAN, R. B., LONG, J. B., BYKOV, V., JACOBSON, A. E., RICE, K. C. AND HOLADAY, J. W.: β-FNA binds irreversibly to opiate receptor complex: In vivo and vitro evidence. J. Pharmacol. Exp. Ther. 247: 405-416, 1988.
51. SANCHEZ-BLAZQUEZ, P. AND GABZON, J.: Evaluation of δ receptor mediation of supraspinal opioid analgesia by in vivo protection against the β-funaltrexamine antagonist effect. Eur. J. Pharmacol. 158: 9-23, 1989.
52. SHIPPENBERG, T. S., BALS-KUBIK, R. AND HERZ, A.: Motivational properties of opioids: Evidence that an activation of δ-opioid receptor mediates reinforcement processes. Brain Res. 436: 234-239, 1987.
53. 1-dopamine receptors in the motivational properties of μ-and κ-opioid agonists. Brain Res. 436: 169-172, 1987.
54. SOFUOGLU, M., PORTOGHESE, P. S. AND TAKEMORI, A. E.: Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: Evidence for delta opioid receptor subtypes. J. Pharmacol. Exp. Ther. 257: 676-680, 1991.
55. SPANAGEL, R., HERZ, A. AND SHIPPENBERG, T. S.: The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem. 55: 1734-1740, 1990.
56. SPYRAKI, C., FIBIGER, N. C. AND PHILLIPS, A. G.: Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmacology 79: 278-283, 1983.
57. SUZUKI, T., FUNADA, M., NARITA, M., MISAWA, M. AND NAGASE, H.: Pertussis toxin abolishes μ- and γ-opioid agonist-induced place preference. Eur. J. Pharmacol. 205: 85-88, 1991.
58. SUZUKI, T., FUNADA, M., NARITA, M., MISAWA, M. AND NAGASE, H.: Morphine-induced place preference in the CXBK mouse: Characteristics of μ opioid receptor subtypes. Brain Res. 602: 45-52, 1993.
59. SUZUKI, T., YOSHIIKE, M., MIZOGUCHI, H., KAMEI, J., MISAWA, M. AND NAGASE, H.: Blockade of δ-opioid receptors prevents morphine-induced place preference in mice. Jpn. J. Pharmacol. 66: 131-137, 1994.
60. SUZUKI, T., MASUKAWA, Y. AND MISAWA, M.: Drug interaction in the reinforcing effects of over-the-counter cough syrups. Psychopharmacology 102: 438-442, 1990.
61. 2 opioid receptor agonists in mice. Psychopharmacology 124: 211-218, 1996.
62. 5]enkephalin. Life Sci. 45: 1001-1008, 1989.
63. WARD, S. J., PORTOGHESE, P. S. AND TAKEMORI, A. E.: Pharmacological profiles of β-funaltrexamine (β-FNA) and β-chlornaltrexamine (β-CNA) on the mouse vas deferens preparation. J. Pharmacol. Exp. Ther. 80: 377-384, 1982.
64. WOLOZIN, B. L. AND PASTERNAK, G. W.: A classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 78: 6181-6185, 1981.